Cardiovascular parameter changes in patients with erectile dysfunction using Pde-5 inhibitors: A study with sildenafil and vardenafil

Journal of Andrology

Volumn 25, Issue 4, 2004, Pages 625-629

  Pomara, Giorgio ^a,d   Morelli, Girolamo ^a   Pomara, Salvatore ^b   Taddei, Stefano ^a   Ghiadoni, Lorenzo ^a   Dinelli, Nicola ^a   Travaglini, Fabrizio ^c   Dicuio, Mauro ^a   Mondaini, Nicola ^c   Salvetti, Antonio ^a   Selli, Cesare ^a  

^a UNIVERSITY OF PISA   (Italy)

^b Civico and Benfratelli Hospital ^*  (Italy)

^c UNIVERSITY OF FLORENCE   (Italy)

^d UNIVERSITY OF PISA   (Italy)

Author keywords

Crossover study; Hypotensive effect; Side effect

Indexed keywords

PHOSPHODIESTERASE V INHIBITOR; SILDENAFIL; VARDENAFIL;

ADULT; AGED; ANTIHYPERTENSIVE ACTIVITY; ARTICLE; CARDIOVASCULAR RESPONSE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIASTOLIC BLOOD PRESSURE; DOSE TIME EFFECT RELATION; ERECTILE DYSFUNCTION; HEART RATE; HUMAN; HYPOTENSION; MALE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; SYSTOLIC BLOOD PRESSURE; VASODILATATION;

EID: 3042855059     PISSN: 01963635     EISSN: None     Source Type: Journal    
DOI: 10.1002/j.1939-4640.2004.tb02833.x     Document Type: Article

References (14)

1. Bischoff E. Vardenafil, a potent and selective inhibitor of phosphodiesterase type 5 increases cGMP in rabbit corpus cavemosum. Int J Impot Res. 2000;12(suppl 3):S65.
2. Cheitlin MD, Hutter AM Jr, Brindis RG, et al. Use of sildenafil (Viagra) in patient with cardiovascular disease. J Am Coll Cardiol. 1999;33: 273-282.
3. De Rose AF, Giglio M, Traverso P, et al. Combined oral therapy with sildenafil and doxazosin for the treatment of non-organic erectile dysfunction refractory to sildenafil monotherapy. Int J Impot Res. 2002; 14:50-53.
4. Jackon G, Benjamin N, Jackson N, et al. Effects of sildenafil citrate on human haemodynamics. Am J Cardiol. 1999;83(suppl 5A):13C-20C.
5. Morales A, Gingell C, Collins M, et al. Clinical safety of oral sildenafil citrate (VIAGRA) in the treatment of erectile dysfunction. Int J Impot Res. 1998;10:69-74.
6. NIH Consensus Panel. Impotence. National Institutes of Health Consensus Conference development panel on impotence. JAMA 1993;270: 83-90.
7. Porst H, Rosen R, Padma-Nathan H, et al. The efficacy and tolerability of vardenafil, a new oral selective Pde-5 inhibitor, in patient with erectile dysfunction: first at-home clinical trial. Int J Impot Res. 2001; 13:192-199.
8. Pryor JP. Vardenafil: update on clinical experience. Int J Impot Res. 2002; 14(suppl):A923.
9. Rosen RC, Riley A, Wagner G, et al. The intemational index of erectile function (IIEF): a multidimensional scale of assessment of erectile dysfunction. Urology. 1997;49:822-830.
10. Thadani U, Smith W, Nash S, et al. The effect of vardenafil, a potent and highly selective phosphodiesterase-5 inhibitor for the treatment of erectile dysfunction, on the cardiovascular response to exercise in patients with coronary artery disease. J Am Coll Cardiol. 2002;40: 2006-2012.
11. Vardi Y, Klein L, Nassar S, et al. Effects of sildenafil citrate (VIAGRA) on blood pressure in normotensive and hypertensive men. Urology. 2002;59:747-752.
12. Vickers MA, Seiler M, Weidner N. Corpora cavernosa ultrastructure in vascular erectile dysfunction. J Urol. 1990;143:1131-1134.
13. Wallis RM, Corbin JD, Francis SH, et al. Tissue distribution of phosphodiesterase families and the effects of sildenafil on tissue cyclic nucleotides, platelet function, and the contractile responses of trabeculae carneae and aortic rings in vitro. Am J Cardiol. 1999;83(5A):3C-12C.
14. World Health Organization. ISH (International Society of Hypertension) Mild Hypertension Liaison Committee, Guidelines Subcommittee. 1999 Guidelines for the management of hypertension. J Hypertens. 1999;17:151-183.